ASPE SCHEDULE 13D: SEC filing
OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC
Filed with the SEC on · accession 0000947871-26-000996
ASPE filed a SCHEDULE 13D (schedule 13d) with the SEC on Nov 6, 2026. A report the company filed with the SEC (the US market regulator). The stock moved +5.8% by the first close after the filing.
Summary of the filing
OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC filed a joint Schedule 13D regarding their position in Aspen Neuroscience, Inc. common stock, indicating a potentially active ownership stake.
Key details
How ASPE stock reacted
Close before
$11.76
Nov 5, 2026
First close after
+5.78%
$12.44
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for ASPE, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ASPE?
Click hereFrequently asked questions
What did ASPE file with the SEC on Nov 6, 2026?
ASPE filed a SCHEDULE 13D (SEC filing). OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC filed a joint Schedule 13D regarding their position in Aspen Neuroscience, Inc. common stock, indicating a potentially active ownership stake.
How do I read a SCHEDULE 13D?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D (schedule 13d): A report the company filed with the SEC (the US market regulator).
How did ASPE stock react to this filing?
ASPE closed at $11.76 before the filing and $12.44 on Nov 6, 2026 (+5.78%).
Other ASPE SEC filings
Get alerts when ASPE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days